Perspectives in Medical Research

Volume: 11 Issue: 3

  • Open Access
  • Editorial

The Unmet Residual Factor For Coronary Artery Disease (CAD):Lipoprotein(a)

1 Consultant Cardiologist, Professor & HOD of Internal Medicine, Prathima Institute of Medical Sciences, Karimnagar
2 Junior Resident, Department of Internal Medicine, Prathima Institute of Medical Sciences, Karimnagar
*Corresponding Author: K Ravinder Reddy, Consultant Cardiologist, Professor & HOD of Internal Medicine, Prathima Institute of Medical Sciences, Karimnagar

Year: 2023, Page: 1-3, Doi: https://doi.org/10.47799/pimr.1103.01

Received: Nov. 30, 2023 Accepted: Dec. 12, 2023 Published: Dec. 12, 2023

Abstract

Keywords:

References

  1. Berg, K . 1963. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 59(3):369–82.

  2. Tsimikas, S . 2017. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69(6):692–711.

  3. Nordestgaard, B G, Chapman, M J & Ray, K . 2010. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–53.

  4. Burgess, Stephen, Ference, Brian A, Staley, James R, Freitag, Daniel F, Mason, Amy M, Nielsen, Sune F, Willeit, Peter, Young, Robin, Surendran, Praveen & Karthikeyan, Savita . 2018. Association of LPA variants with risk of coronary disease and the implications for lipoprotein (a)-lowering therapies: a Mendelian randomization analysis. JAMA cardiology 3(7):619–627.

  5. Landray, M J, Haynes, R & Hopewell, J C . 2014. Effects of extended-release niacin with laropiprant in high risk patients. N Engl J Med 317(3):203–215.

  6. Boden, W E, Probstfield, J L & Anderson, T . 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365(24):2255–67.

  7. Cannon, C P, Shah, S & Dansky, H M . 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl Med 363:2406–2421.

  8. Viney, N J, Van Capelleveen, J C & Geary, R S . 2016. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–53.

  9. Iyengar, Shamanna S, Puri, Raman & Narasingan, SN . 2016. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016: Part 1-executive summary. Journal of Clinical and Preventive Cardiology 5(2):51–61.

Cite this article

Reddy KR, Gowtham S, Reddy Challa T. The Unmet Residual Factor For Coronary Artery Disease (CAD):Lipoprotein(a). Perspectives in Medical Research. 2023;11(3):1-3 DOI: 10.47799/pimr.1103.01

Views
285
Downloads
90
Citations